Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trial

Marcus Maurer; Sarbjit S Saini; Kristi McLendon; Paul Wabnitz; Sunghyun Kim; Keumyoung Ahn; Suyoung Kim; Sewon Lee; Clive Grattan

doi:10.1002/clt2.12204

Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trial

Clin Transl Allergy. 2022 Nov;12(11):e12204. doi: 10.1002/clt2.12204.

Authors

Marcus Maurer^{1

2}, Sarbjit S Saini³, Kristi McLendon⁴, Paul Wabnitz⁵, Sunghyun Kim⁶, Keumyoung Ahn⁶, Suyoung Kim⁶, Sewon Lee⁶, Clive Grattan⁷

Affiliations

¹ Institute of Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
² Allergology and Immunology, Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Berlin, Germany.
³ Johns Hopkins University School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
⁴ Nucleus Network Pty Ltd, Herston, Queensland, Australia.
⁵ cPHARMA Pty Ltd, Adelaide, South Australia, Australia.
⁶ Celltrion, Inc., Incheon, Republic of Korea.
⁷ St John's Institute of Dermatology, Guy's Hospital, London, UK.

Abstract

Background: CT-P39 is being developed as a biosimilar of reference omalizumab. This study aimed to assess the pharmacokinetic equivalence of CT-P39 to European Union-approved and United States-licensed reference omalizumab (EU- and US-omalizumab, respectively).

Methods: This two-part, randomised, parallel-group, double-blind Phase 1 trial (NCT04018313) was conducted in healthy individuals with a total immunoglobulin E (IgE) level ≤100 international units (IU)/ml at screening. In part 2, described herein, participants were randomised (1:1:1) to receive a single 150 mg subcutaneous dose of CT-P39, EU-omalizumab, or US-omalizumab. The primary endpoint was pharmacokinetic equivalence in terms of area under the concentration-time curve (AUC) from time zero to the last quantifiable concentration (AUC_0-last ), AUC from time zero to infinity (AUC_0-inf ), and maximum serum concentration (C_max ). Equivalence was concluded if 90% confidence intervals (CIs) of the geometric least-squares means ratios were contained within the predefined 80%-125% equivalence margin. Additional pharmacokinetic parameters, pharmacodynamics, safety, and immunogenicity were also evaluated.

Results: Overall, 146 participants were randomised (CT-P39, N = 47; EU-omalizumab, N = 49; US-omalizumab, N = 50). For all primary pharmacokinetic parameters, 90% CIs for pairwise treatment comparisons were within the 80%-125% equivalence margin, demonstrating pharmacokinetic equivalence. Decreases in free IgE and increases in total IgE serum concentrations were comparable across groups. CT-P39 was well tolerated. Safety endpoints were comparable across groups: there were no treatment-related serious adverse events, deaths, or discontinuations due to treatment-emergent adverse events.

Conclusions: CT-P39 was well tolerated and demonstrated pharmacokinetic equivalence with EU-omalizumab and US-omalizumab following administration of a single dose in healthy individuals.

Keywords: CT-P39; biosimilar; immunoglobulin E; omalizumab; pharmacokinetics.

Grants and funding

Celltrion, Inc.